US National Institutes of Health (NIH) Reveals First Beneficiaries of Its Rapid Accelerated Diagnosis (RADx) Program and Based in San Mateo spiral as a result, receives federal funding of $ 33 million. Helix is a healthcare startup founded in 2015 that focuses on research based on personal genomics, but the company has also developed a COVID-19 test that detects the presence of SARS-CoV-2 using RT-PCR techniques.
The funding will be used to support Helix’s efforts to scale up COVID-19 testing efforts to reach this rate of 100,000 tests per day this fall, and then further increase throughput. The Helix test received FDA emergency use (EUA) approval earlier this month, and has since been available across the US, promising “next day” results.
Helix has also been filed for EUA for a second type of test, the NGS test, which offers higher throughput for more testing, as well as increased sensitivity to the actual detection of the presence of the virus to avoid false negative results. This test, if approved, will be key to helping Helix achieve a much larger scale of testing capabilities, which is the ultimate goal of the RADx program.
This second test system, which is currently seeking approval, will be able to process up to 25,000 tests per day, and uses a different method that will also help reduce pressure on the supply chain.